First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Sophie Postel-VinayVincent K LamWilleke RosTodd M BauerAaron R HansenDaniel C ChoF Stephen HodiJan H M SchellensJennifer K LittonSandrine AspeslaghKaren A AutioFrans L OpdamMeredith McKeanNeeta SomaiahStephane ChampiatMehmet AltanAnna SpreaficoOsama RahmaElaine M PaulChristoph M AhlersHelen ZhouHerbert StruemperShelby A GormanMaura WatmuffKaitlin M YablonskiNiranjan YanamandraMichael J ChisamoreEmmett V SchmidtAxel HoosAurélien MarabelleJeffrey S WeberJohn V HeymachPublished in: Journal for immunotherapy of cancer (2023)
NCT02528357.